The diagnosis of pituitary adenomas (PAs), also called pituitary tumors or neuroendocrine tumors (PitNETs) currently involves assessment of blood/plasma hormone levels and traditional neuroradiological techniques, with magnetic resonance imaging (MRI) being of particular significance. However, Positron Emission Tomography- computerized tomography (PET-CT) has been gaining a more substantial role both for the diagnosis and management of PAs. The present systematic review analyzes the most widely used radiopharmaceuticals in the evaluation of pituitary disorders. We explore the potential utilization of PET with multiple radiopharmaceuticals for individualized diagnosis and therapeutic strategies, highlighting both the constraints and merits of this constantly evolving technique and application in clinical practice.
Keywords: Acromegaly; Corticotroph adenoma; Cushing’s disease; Lactotroph adenoma; PET-TC; Pituitary adenoma; Prolactinoma; Somatotroph adenoma.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.